Journal
ACTA BIOMATERIALIA
Volume 134, Issue -, Pages 559-575Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2021.07.021
Keywords
Dually targeted nanoparticles; Bioinspired nanovesicles; Advanced prostate cancer; Prostate-specific membrane antigen (PSMA); Doxorubicin-PSA prodrug; Cancer therapy
Funding
- EPSRC [EP/M008657/1] Funding Source: UKRI
Ask authors/readers for more resources
Prostate cancer is the second-leading cancer in men with limited treatment options. PSA and PSMA have been exploited as therapeutic targets, and several activatable prodrugs have been developed. Dually targeted PSA/PSMA nanovesicles have been engineered for advanced prostate cancer, providing highly selective treatment options.
Prostate cancer (PC) is second-leading cancer in men, with limited treatment options available for men with advanced and metastatic PC. Prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) have been exploited as therapeutic targets in PC due to their upregulation in the advanced stages of the disease. To date, several PSA-and PSMA-activatable prodrugs have been developed to reduce the systemic toxicity of existing chemotherapeutics. Bioinspired nanovesicles have been exploited in drug delivery, offering prolonged drug blood circulation and higher tumour accumulation. For the first time, this study describes the engineering of dually targeted PSA/PSMA nanovesicles for advanced PC. PSMA-targeted bioinspired hybrids were prepared by hydrating a lipid film with anti-PSMA-U937 cell membranes and DOX-PSA prodrug, followed by extrusion. The bioinspired hybrids were characterised using dynamic light scattering, transmission electron microscopy, Dot blot, flow cytometry and Western blot. Cellular binding and toxicity studies in PC cancer cell lines were carried out using flow cytometry, confocal microscopy, and resazurin assay. Finally, tumour targeting and therapeutic efficacy studies were performed in solid and metastatic C4-2B-tumor-bearing mice. Interestingly, our PSMA-targeted hybrids demonstrated high cell uptake in PSMA-expressing cells with significant accumulation in solid and metastatic C4-2B tumour tissues following intravenous administration. More promisingly, our dually targeted PSA/PSMA hybrid significantly slowed down the C4-2B tumour growth in vivo , compared to free DOX-PSA and non-targeted PSA-hybrid. Our PSA/PSMA bioinspired hybrid could offer a highly selective treatment for advanced PC with lower side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available